TEVA PHARMA INDUSTRIES LTD ADR

NYSE: TEVA (Teva Pharmaceutical Industries)

Last update: 28 Aug, 1:50AM

18.05

-0.10 (-0.55%)

  • 1D -0.55%
  • 5D -10.06%
  • 1M -2.17%
  • 6M 35.61%
  • YTD -15.26%
  • 1Y 0.56%
  • 5Y 94.29%
Previous Close 18.15
Open 18.22
Volume 8,579,578
Avg. Volume (3M) 11,491,728
Market Cap 20,763,815,936
Price / Earnings (Forward) 7.06
Price / Sales 1.38
Price / Book 3.37
52 Weeks Range
12.47 (-30%) — 22.80 (26%)
Earnings Date 30 Jul 2025
Profit Margin -7.74%
Operating Margin (TTM) 18.22%
Diluted EPS (TTM) -1.15
Quarterly Revenue Growth (YOY) 1.90%
Total Debt/Equity (MRQ) 270.20%
Current Ratio (MRQ) 1.03
Operating Cash Flow (TTM) 1.27 B
Levered Free Cash Flow (TTM) 1.66 B
Return on Assets (TTM) 5.27%
Return on Equity (TTM) -19.11%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Bullish Bullish
Drug Manufacturers - Specialty & Generic (Global) Bullish Bullish
Stock Teva Pharmaceutical Industries Mixed Bullish

AIStockmoo Score

1.5
Analyst Consensus 3.5
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages -3.5
Technical Oscillators 4.0
Average 1.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
TEVA 21 B - - 3.37
ZTS 63 B 1.02% 24.29 13.04
HLN 47 B 1.11% 25.04 1.85
TAK 47 B 4.61% 50.52 0.980
RDY 12 B 54.73% 18.87 2.97
BHC 2 B - 24.88 -

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Large Value
% Held by Institutions 67.15%

Ownership

Name Date Shares Held
Menora Mivtachim Holdings Ltd. 31 Mar 2025 29,189,316
Migdal Insurance & Financial Holdings Ltd. 31 Mar 2025 26,335,422
52 Weeks Range
12.47 (-30%) — 22.80 (26%)
Price Target Range
0.000 (-100%) — 26.00 (44%)
High 26.00 (JP Morgan, 44.04%) Buy
26.00 (UBS, 44.04%) Buy
Median 26.00 (44.04%)
Average 26.00 (44.04%)
Total 2 Buy
Avg. Price @ Call 19.64
Firm Date Target Price Call Price @ Call
JP Morgan 03 Oct 2025 26.00 (44.04%) Buy 20.01
UBS 24 Sep 2025 26.00 (44.04%) Buy 19.27

No data within this time range.

  • 3M
Date Type Details
10 Oct 2025 Announcement Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
10 Oct 2025 Announcement FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
10 Oct 2025 Announcement FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
26 Sep 2025 Announcement Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
25 Sep 2025 Announcement Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
25 Sep 2025 Announcement Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
25 Sep 2025 Announcement Teva Releases Q3 2025 Aide Memoire
25 Sep 2025 Announcement Teva Releases Q3 2025 Aide Memoire
25 Sep 2025 Announcement Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
24 Sep 2025 Announcement Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
24 Sep 2025 Announcement Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
20 Sep 2025 Announcement Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
20 Sep 2025 Announcement Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
20 Sep 2025 Announcement New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
20 Sep 2025 Announcement New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
16 Sep 2025 Announcement Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
16 Sep 2025 Announcement Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
16 Sep 2025 Announcement Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
10 Sep 2025 Announcement Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
09 Sep 2025 Announcement Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
09 Sep 2025 Announcement Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
02 Sep 2025 Announcement Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
02 Sep 2025 Announcement Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
28 Aug 2025 Announcement Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
28 Aug 2025 Announcement Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
25 Aug 2025 Announcement Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
21 Aug 2025 Announcement Immuneering Announces $25 Million Private Placement
13 Aug 2025 Announcement Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
06 Aug 2025 Announcement FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
06 Aug 2025 Announcement FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
30 Jul 2025 Announcement Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
30 Jul 2025 Announcement Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
Show more
5Y Average Dividend Yield 0.00%
Ex Date Announcement Date Payment Date Details
27 Nov 2017 06 Nov 2017 12 Dec 2017 0.085 Cash
25 Aug 2017 - 14 Sep 2017 0.07225 Cash
01 Jun 2017 - 22 Jun 2017 0.289 Cash
28 Feb 2017 - 20 Mar 2017 0.289 Cash
01 Dec 2016 - 20 Dec 2016 0.289 Cash
18 Aug 2016 - 08 Sep 2016 0.289 Cash
20 May 2016 - 07 Jun 2016 0.289 Cash
25 Feb 2016 - 14 Mar 2016 0.289 Cash
13 Nov 2015 - 03 Dec 2015 0.289 Cash
18 Aug 2015 - 03 Sep 2015 0.289 Cash
15 May 2015 - 04 Jun 2015 0.289 Cash
17 Feb 2015 - 03 Mar 2015 0.293636 Cash
13 Nov 2014 - 02 Dec 2014 0.269593 Cash
19 Aug 2014 - 04 Sep 2014 0.291112 Cash
16 May 2014 - 02 Jun 2014 0.29777 Cash
20 Feb 2014 - 10 Mar 2014 0.293019 Cash
18 Nov 2013 - 03 Dec 2013 0.277541 Cash
16 Aug 2013 - 03 Sep 2013 0.273656 Cash
16 May 2013 - 03 Jun 2013 0.268249 Cash
19 Feb 2013 - 07 Mar 2013 0.266857 Cash
13 Nov 2012 - 03 Dec 2012 0.202399 Cash
13 Aug 2012 - 04 Sep 2012 0.208281 Cash
17 May 2012 - 04 Jun 2012 0.196042 Cash
23 Feb 2012 - 13 Mar 2012 0.197212 Cash
10 Nov 2011 - 07 Dec 2011 0.17539 Cash
09 Nov 2011 - 07 Dec 2011 0.171904 Cash
04 Aug 2011 - 25 Aug 2011 0.196304 Cash
03 Aug 2011 - 25 Aug 2011 0.199624 Cash
19 May 2011 - 07 Jun 2011 0.199925 Cash
10 Feb 2011 - 07 Mar 2011 0.216813 Cash
08 Nov 2010 - 06 Dec 2010 0.173008 Cash
02 Aug 2010 - 26 Aug 2010 0.166994 Cash
10 May 2010 - 04 Jun 2010 0.163153 Cash
19 Feb 2010 - 17 Mar 2010 0.164033 Cash
06 Nov 2009 - 04 Dec 2009 0.125431 Cash
03 Aug 2009 - 27 Aug 2009 0.124804 Cash
08 May 2009 - 03 Jun 2009 0.120261 Cash
23 Feb 2009 - 19 Mar 2009 0.111992 Cash
07 Nov 2008 - 05 Dec 2008 0.09309 Cash
01 Aug 2008 - 27 Aug 2008 0.10421 Cash
13 May 2008 - 05 Jun 2008 0.11255 Cash
12 May 2008 - 05 Jun 2008 0.10919 Cash
18 Feb 2008 - 13 Mar 2008 0.10429 Cash
15 Feb 2008 - 13 Mar 2008 0.10174 Cash
02 Nov 2007 - 28 Nov 2007 0.084 Cash
10 Aug 2007 - 06 Sep 2007 0.08015 Cash
10 May 2007 - 05 Jun 2007 0.0833 Cash
16 Feb 2007 - 15 Mar 2007 0.07866 Cash
10 Nov 2006 - 06 Dec 2006 0.06569 Cash
11 Aug 2006 - 08 Sep 2006 0.06434 Cash
12 May 2006 - 07 Jun 2006 0.06257 Cash
06 Mar 2006 - 30 Mar 2006 0.06072 Cash
10 Nov 2005 - 07 Dec 2005 0.05188 Cash
11 Aug 2005 - 07 Sep 2005 0.05431 Cash
05 May 2005 - 01 Jun 2005 0.0559 Cash
17 Feb 2005 - 17 Mar 2005 0.0559 Cash
09 Nov 2004 - 06 Dec 2004 0.0414 Cash
09 Aug 2004 - 07 Sep 2004 0.0401 Cash
10 May 2004 - 07 Jun 2004 0.0768 Cash
20 Feb 2004 - 22 Mar 2004 0.0781 Cash
13 Nov 2003 - 12 Dec 2003 0.0587 Cash
08 Aug 2003 - 08 Sep 2003 0.0596 Cash
08 May 2003 - 06 Jun 2003 0.0581 Cash
24 Feb 2003 - 24 Mar 2003 0.0546 Cash
07 Nov 2002 - 06 Dec 2002 0.0738 Cash
19 Aug 2002 - 16 Sep 2002 0.0738 Cash
20 May 2002 - 17 Jun 2002 0.0701 Cash
15 Feb 2002 - 18 Mar 2002 0.0772 Cash
16 Nov 2001 - 17 Dec 2001 0.0531 Cash
20 Aug 2001 - 17 Sep 2001 0.0498 Cash
17 May 2001 - 15 Jun 2001 0.0486 Cash
08 Mar 2001 - 06 Apr 2001 0.0477 Cash
16 Nov 2000 - 15 Dec 2000 0.0407 Cash
24 Aug 2000 - 21 Sep 2000 0.0415 Cash
19 May 2000 - 19 Jun 2000 0.0405 Cash
17 Feb 2000 - 27 Mar 2000 0.0838 Cash
04 Nov 1999 - 30 Nov 1999 0.0529 Cash
18 Aug 1999 - 13 Sep 1999 0.0527 Cash
21 May 1999 - 15 Jun 1999 0.054 Cash
08 Mar 1999 - 30 Mar 1999 0.055 Cash
20 Nov 1998 - 11 Dec 1998 0.053 Cash
21 Aug 1998 - 11 Sep 1998 0.058 Cash
21 May 1998 - 22 Jun 1998 0.0639 Cash
12 Mar 1998 - 31 Mar 1998 0.0649 Cash
20 Nov 1997 - 09 Dec 1997 0.0666 Cash
25 Aug 1997 - 11 Sep 1997 0.0667 Cash
23 May 1997 - 12 Jun 1997 0.069 Cash
07 Mar 1997 - 26 Mar 1997 0.0695 Cash
20 Nov 1996 - 09 Dec 1996 0.0468 Cash
26 Aug 1996 - 12 Sep 1996 0.0492 Cash
23 May 1996 - 12 Jun 1996 0.0477 Cash
07 Mar 1996 - 26 Mar 1996 0.0504 Cash
20 Nov 1995 - 07 Dec 1995 0.0485 Cash
14 Aug 1995 - 30 Aug 1995 0.0488 Cash
17 May 1995 - 07 Jun 1995 0.051 Cash
07 Mar 1995 - 04 Apr 1995 0.0512 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2017 0.735 4 3.88
2016 1.16 4 3.19
2015 1.16 4 1.77
2014 1.15 4 2.00
2013 1.09 4 2.71
2012 0.804 4 2.15
2011 1.16 6 2.87
2010 0.667 4 1.28
2009 0.482 4 0.86
2008 0.625 6 1.47
2007 0.326 4 0.70
2006 0.253 4 0.82
2005 0.218 4 0.51
2004 0.236 4 0.79
2003 0.231 4 0.82
2002 0.295 4 1.53
2001 0.199 4 1.29
2000 0.207 4 1.13
1999 0.215 4 2.40
1998 0.240 4 4.72
1997 0.272 4 4.60
1996 0.194 4 3.09
1995 0.200 4 3.44
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria